Citations

Clear

626 citation(s) found for "Mehta, SH".

Comparative Performance of Scribe and Database Search Engines in Metaproteomic Profiling of a Ground-Truth Microbiome Dataset
Rajczewski, Andrew T. , Mehta, Subina , Wagner, Reid , Gabriel, Wassim , Johnson, James E. , Do, Katherine , Vintila, Simina , Wilhelm, Mathias , Kleiner, Manuel , Searle, Brian C. , Griffin, Timothy J , Jagtap, Pratik D , Searle, Brian C , Griffin, Timothy J. , Jagtap, Pratik

Mayo Clinic

No container title available | May 20, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.05.15.654320 | PMID 40475569 Get It

ABSTRACT Mass spectrometry-based metaproteomics, the identification and quantification of thousands of proteins expressed by complex microbial communities, has become pivotal for unraveling functional interactions within microbiomes. However, metaproteomics data analysis encounters many challenges, including the search of tandem mass spectra against a protein sequence database using proteomics database search algorithms. We used a ground-truth dataset to assess a spectral library searching method against established database searching approaches. Mass spectrometry data collected by data-dependent acquisition (DDA-MS) was analyzed using database searching approaches (MaxQuant and FragPipe), as well as using Scribe with Prosit predicted spectral libraries. We used FASTA databases that included protein sequences from microbial species present in the ground-truth dataset along with background protein sequences, to estimate error rates and assess the effects on detection, peptide-spectral match quality, and quantification. Using the Scribe search engine resulted in more proteins detected at a 1% false discovery rate (FDR) compared to MaxQuant or FragPipe, while FragPipe detected more peptides verified by PepQuery. Scribe was able to detect more low-abundance proteins in the microbiome dataset and was more accurate in quantifying the microbial community composition. This research provides insights and guidance for metaproteomics researchers aiming to optimize results in their analysis of DDA-MS data.
Clinical phenotypes among patients with familial forms of Chiari malformation type 1
Mekbib, Kedous Y. , Allington, Garrett , Zhao, Shujuan, Fortes, Carla, Shohfi, John, Nelson‐Williams, Carol , Butler, William E. , Alper, Seth L. , Jackson, Eric M., Muñoz, William , Mehta, Neel H. , Fan, Baojian , DeSpenza, Tyrone , Kahle, Kristopher T.

Mayo Clinic

Journal of Neurosurgery: Pediatrics | May 2, 2025 | Volume: 36 | Issue: 1 | Pages: 109-118

10.3171/2025.1.peds24187 | PMID 40315599 Get It

OBJECTIVE Chiari malformation type 1 (CM1) is the most common neurological disorder of the craniocervical junction. CM1 is characterized by cerebellar tonsillar herniation below the foramen magnum, causing CSF obstruction and neural compression. Patients with CM1 suffer from highly variable symptoms, progression, comorbidities, and outcomes, partly due to poor understanding of CM1 pathogenesis. In this paper, the authors present the only familial CM1 cohort study to statistically assess intrafamilial clinical phenotypes to date. METHODS Comprehensive medical, surgical, and family histories and neuroimaging were collected from families with multiple CM1-affected family members. Univariate analysis was performed for each symptom, comorbidity, or surgery to compare observed versus expected frequencies of affected patients with another CM1-affected family member with the same clinical characteristic. RESULTS Twenty-four new familial CM1 cases (totaling 57 patients with CM1) are presented. Intrafamilial similarities were identified for age of onset, symptoms such as headaches (p = 0.007) and neck pain (p = 0.018), neurological comorbidities such as syringomyelia (p = 0.003) and hydrocephalus (p = 0.0001), neurodevelopmental conditions such as dyslexia (p < 0.0001), and connective tissue disorders (CTDs) such as Ehlers-Danlos syndrome (p < 0.0001). CONCLUSIONS These results suggest that CM1 and its associated clinical phenotypes, including age of onset, clinical symptoms, neurological comorbidities, neurodevelopmental conditions, and CTDs, are genetically influenced. Whole-exome sequencing of CM1 patient-parent trios has the potential to identify the genetic determinants of CM1, with implications for neurosurgical management.
Impact of Long‐Term Use of Anticoagulants Among Elderly Patients Undergoing Left Atrial Appendage Occlusion Procedures in the United States: A Retrospective Cohort Study
Mehta, Samay , Sekhon, Manraj, Rajotia, Arush , Gandhi, Haresh , Raj, Kavin , Singh, Jarmanjeet , Verma, Renuka, Sakthivel, Hemamalini, Ramphul, Kamleshun, Singh, Swaiman, Mehta, Samay , Dhaliwal, Jasninder Singh , Sekhon, Manraj, Ahmed, Mushood , Ahmed, Raheel

Mayo Clinic

Health Science Reports | April 30, 2025 | Volume: 8 | Issue: 5 | Pages: No page available

10.1002/hsr2.70812 | PMID 40309619 Get It

Pentoxifylline use in alcohol-associated hepatitis with acute kidney injury does not improve survival: a global study
Idalsoaga, Francisco , Caldentey, Vicente, Arnold, Jorge , Maiwall, Rakhi , Qian, Steve , Elfeki, Mohamed A. , Khan, Mohammad Qasim, Mortuza, Rokhsana , Malhi, Gurpreet, Islam, Alvi H. , Ramírez, Carolina , Echavarria, Victor, Poca, María , Cuyàs, Berta , Ventura‐Cots, Meritxell , Tijera, María Fátima Higuera-De La, Al‐Karaghouli, Mustafa , Havaj, Daniel Ján , Shah, Vijay H. , Kamath, Patrick S. , SIMONETTO, DOUGLAS, Havaj, Daniel J , Shah, Vijay, Arab, Juan P , Poca, Maria , Ventura Cots, Meritxell , Elfeki, Mohamed A , Cuyas, Berta , Díaz, Luis Antonio , Dunn, Winston , Mehta, Heer, Ayares, Gustavo , Sarin, Shiv Kumar , Zhang, Wei , Simonetto, Douglas A. , Singal, Ashwani K. , Khan, Mohammad Qasim, Guizzetti, Leonardo , Cabezas, Joaquín , Echavarria, Victor, Soriano, German , Abraldeṣ, Juan G. , Skladaný, Lubomir , Rincón, Diego , Arrese, Marco , Bataller, Ramon A , Arab, Juan Pablo

Mayo Clinic

eGastroenterology | April 20, 2025 | Volume: 3 | Issue: 2 | Pages: e100179

10.1136/egastro-2024-100179 | PMID 40276593 Get It

Background Severe alcohol-associated hepatitis (sAH) is a life-threatening condition with high mortality, where corticosteroid use is the only treatment that has shown short-term benefits. Pentoxifylline, an anti-tumour necrosis factor-alpha agent, has been proposed for its potential to improve outcomes, especially in patients with acute kidney injury (AKI). We aimed to evaluate the impact of pentoxifylline on mortality in patients with sAH and AKI in a well-characterised global cohort. Methods We conducted a retrospective, registry-based study including patients meeting the National Institute on Alcohol Abuse and Alcoholism clinical criteria for sAH and AKI. Mortality was the primary endpoint, with liver transplantation as a competing risk. Statistical analysis included Cox regression and Kaplan-Meier survival estimates. Results We included 525 patients from 20 centres across eight countries. The median age was 48 years, with 26.1% females, and 76.9% had a history of cirrhosis. Multivariable Cox regression models showed that pentoxifylline use was not associated with survival (HR 1.20, 95% CI 0.85 to 1.69, p=0.291). Factors associated with mortality included age (HR 1.23, 95% CI 1.10 to 1.36, p<0.001), Model for End-Stage Liver Disease score at admission (HR 1.06, 95% CI 1.04 to 1.08, p<0.001) and renal replacement therapy use (HR 1.39, 95% CI 1.05 to 1.84, p=0.019). The main causes of death were multiple organ failure (42%), infections (10%), oesophageal varices bleeding (7%) and renal failure (6%). Conclusion Pentoxifylline showed no significant benefit on mortality in patients with sAH and AKI. Further studies are needed to refine treatment strategies for this high-risk group.
Improved Survival and Prognostication in Melanoma Patients With Brain Metastases: An Update of the Melanoma Graded Prognostic Assessment
Sperduto, Paul W. , Marqueen, Kathryn E. , Chang, Enoch , Li, Jing , Davies, Michael A. , Ebner, Daniel K. , Breen, William G. , Lamba, Nayan , Shih, Helen A. , Mahal, Amandeep R. , Rahman, Rifaquat , Ankrah, Nii, Boggs, Drexell H. , Lewis, Calvin D. , Hyer, Daniel E. , Johri, Fasila, Soliman, Hany , Masucci, Laura , Chiang, Veronica , Phuong, Christina , Dajani, Salah, Wan, Zihan, Niedzwiecki, Donna , Vaios, Eugene , Pasetsky, Jared , Wang, Tony J. C. , Kotecha, Rupesh , Ross, Richard B. , Rusthoven, Chad G. , Nakano, Toshimichi , Tawbi, Hussein A. , Edwards, Donna , Kim, Michelle M , Rahman, Rifaquat , Boggs, Drexell H , Lewis, Calvin , Hyer, Daniel , Buatti, John M , Aneja, Sanjay , Chiang, Veronica , Phuong, Christina , Braunstein, Steve , Sachdev, Sean , Niedzwiecki, Donna , Vaios, Eugene , Pasetsky, Jared , Wang, Tony J C , Kotecha, Rupesh , Ross, Richard B , Rusthoven, Chad G , Nakano, Toshimichi , Tawbi, Hussein , Mehta, Minesh P , Shih, Helen A , Kim, Michelle M. , Buatti, John M. , Roberge, David , Braunstein, Steve , Kirkpatrick, John P. , Kütük, Tuğçe , Mehta, Minesh P.

Mayo Clinic

Journal of Clinical Oncology | April 17, 2025 | Volume: 43 | Issue: 16 | Pages: 1910-1919

10.1200/jco-24-01351 | PMID 40245362 Get It

PURPOSE Survival for patients with melanoma has recently improved. The propensity of melanoma to metastasize to the brain remains a common and serious feature of this disease. The purposes of this study were to evaluate prognostic factors for patients with newly diagnosed melanoma brain metastases (MBMs) in a large cohort treated with modern multimodal therapies, compare those results with those in prior eras, and update the Melanoma Graded Prognostic Assessment (GPA). METHODS Univariable and multivariable (MVA) analyses of prognostic factors and treatments associated with survival were performed on 1,796 patients with newly diagnosed MBM treated between January 01, 2015, and December 31, 2021, using a multi-institutional retrospective database. Multiple imputation was used to address missingness of potential predictors. Significant variables in combined MVA were used to update the Melanoma GPA. Comparisons were made with legacy cohorts. RESULTS Median survivals for cohorts A (1985-2007, n = 481), B (2006-2015, n = 823), and C (2015-2021, n = 1,796) were 6.7, 9.8, and 16.6 months and median follow-up times were 40.1, 43.6, and 48.8 months, respectively. In combined MVA, significant prognostic factors for survival were higher Karnofsky Performance Status, fewer MBMs, absence of extracranial metastases, lower serum lactate dehydrogenase, and no immunotherapy before MBM. These factors were incorporated into the updated Melanoma GPA. The combined median and 3-year survivals for patients with GPA 0-1, 1.5-2, and 2.5-4.0 were 5.4, 13.2, and 43.2 months and 12.4%, 28.8%, and 51.6%, respectively. CONCLUSION Prognostic factors have changed and survival has improved for patients with MBM but varies widely by GPA. The updated Melanoma GPA calculator (BrainMetGPA), available free online, can be used to estimate survival, individualize treatment, stratify clinical trials, guide surveillance, and augment clinical trial eligibility. Multidisciplinary treatment is essential. Trials are needed to elucidate the optimal sequencing of various therapeutic modalities.
Associations Between Neuropsychiatric Symptom Burden, Change in Cognitive Status and Survival in Autopsy-confirmed Cohorts of Lewy Body Disease and Alzheimer’s Disease (P1-5.028)
Chiu, Shannon , Shill, Holly A. , Mehta, Shyamal H. , Driver‐Dunckley, Erika , Belden, Christine M. , Tremblay, Cécilia , Zhang, Nan , Adler, Charles H. , Shprecher, David , Serrano, Geidy E. , Beach, Thomas, Atri, Alireza , Choudhury, Parichita

Mayo Clinic

Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000209009 Get It

Digital Health Intervention to Promote Lifelong Specialized Care in Adults with Congenital Heart Disease: Study Design
Agarwal, Anushree , Valente, J. , Buernostro, Karina, Macholl, Katelyn , Mehta, J. L., Reddy, Keerthana , Manayan, Karina , Parang, Kim , Sparks, Aleah , Li, Kunyi , Ahuja, Pranav , Sun, Kevin , Payton, Kimberly , Norris, Mark D. , Moons, Philip , Okumura, Megumi J. , Marcus, Gregory M. , Gurvitz, Michelle , Bravo-Jaimes, Katia , Marcus, Gregory M , Valente, Joseph, Buenrostro, Karina , Mehta, Juhi, Bravo‐Jaimes, Katia , Reardon, Leigh Christopher

Mayo Clinic

No container title available | April 2, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.03.31.25324723 | PMID 40236434 Get It

Abstract Background Adults with congenital heart disease (ACHD) frequently experience gaps in lifelong ACHD specialty care, leading to preventable complications, hospitalizations, and premature mortality. However, effective, scalable, accessible, and sustainable strategies to reduce these gaps are lacking. Digital health offers potential solutions but requires a rigorous scientific approach in its design to address the needs of the target population. Objective To describe the development of a theory-based, community co-designed digital health intervention to improve lifelong ACHD care. Methods We integrated theory-based behavioral frameworks, semi-structured qualitative interviews with patients and clinicians, and a community-engaged approach to develop a digital health intervention for ACHD. The primary behavioral target was completing an ACHD specialist appointment. We conducted Capability, Opportunity, Motivation, and Behavior (COM-B)-guided semi-structured interviews with ACHD patients and clinicians to identify barriers to specialized care amenable to a digital intervention and patient-centered goals for the digital tool. The community partners helped develop key intervention objectives, create a theory-driven framework, and specify how each intervention component targets specific COM-B barriers. Results We interviewed 54 participants (37 ACHD patients and 17 clinicians) and engaged 21 community partners representing 4 advocacy organizations. Design objectives emphasized addressing patient loneliness, ensuring accessibility and credibility, and enabling scalability while centering patient perspectives. Participants identified four priorities: providing credible resources, uplifting patient voices, customizing to patient needs, and centering positivity and joy. The digital tool, named by community partners as Empower My Congenital Heart (EMCH), was designed within the web- and mobile-based, Apple- and Android-compatible, Eureka Digital Research platform (University of California, San Francisco). Key intervention components included educational modules, peer support, appointment planning nudges, and a digital medical passport. The EMCH’s theory-driven framework specifies how each intervention component targets specific COM-B barriers to specialized ACHD care. Conclusions The theory-driven, community co-designed EMCH digital tool is a rapidly scalable approach to improve guideline-recommended specialized ACHD care. Future studies will evaluate the acceptability, feasibility, effectiveness, and implementation outcomes to provide insight into a novel tool to reduce preventable morbidity and mortality in ACHD. Trial Registration The National Clinical Trial number for this study is NCT06581484 .
Moderate alcohol-associated hepatitis: A real-world multicenter study
Idalsoaga, Francisco , Díaz, Luis Antonio , Dunn, Winston , Muñoz, Karen E., Caldentey, Vicente, Arnold, Jorge , Ayares, Gustavo , Mortuza, Rokhsana , Maiwall, Rakhi , Qian, Steve , Elfeki, Mohamed A. , Ramírez, Carolina , Malhi, Gurpreet, Ahmed, Adan, Homsi, Hoomam , Abid, Zinia, Echavarría, Victor, Poca, María , Cuyàs, Berta , Ventura‐Cots, Meritxell , Higuera‐de‐la‐Tijera, Fátima , Ayala-Valverde, María , Pérez, Diego , Gómez, Jaime , Abraldes, Juan, Al‐Karaghouli, Mustafa , Jalal, Prasun K. , Ibrahim, Mohamad Ali , García–Tsao, Guadalupe , Havaj, Daniel Ján , Sulejova, Karolina, Chacko, Kristina R. , Yaquich, Pamela, Toro, Luis, Shah, Vijay H. , Kamath, Patrick S. , Mehta, Heer , Arnold, Jorge , Ayares, Gustavo , Mortuza, Rokhsana , Sarin, Shiv Kumar , Maiwall, Rakhi , Qian, Steve , Simonetto, Douglas A , Singal, Ashwani K , Ramirez-Cadiz, Carolina , Poca, Maria , Soriano, German , Cuyas, Berta , Ventura Cots, Meritxell , Higuera-De La Tijera, Fatima , Ayala-Valverde, María , Jalal, Prasun K , Skladaný, Lubomir , Havaj, Daniel J , Chacko, Kristina R , Restrepo, Juan C , Shah, Vijay, Arrese, Marco , Kamath, Patrick S , Bataller, Ramon A , Díaz, Luis A , Elfeki, Mohamed A , Dunn, Winston , Echavaría, Victor , Muñoz, Karen, Zhang, Wei , Simonetto, Douglas A. , Singal, Ashwani K. , Ahmed, Adan, Abid, Zinia, Cabezas, Joaquín , Abraldeṣ, Juan G. , Goyes, Daniela , Selčanová, Světlana Adamcová , Rincón, Diego , Arrese, Marco , Arab, Juan Pablo

Mayo Clinic

Hepatology Communications | March 28, 2025 | Volume: 9 | Issue: 4 | Pages: No page available

10.1097/hc9.0000000000000673 | PMID 40131003 Get It

Background: Severe alcohol-associated hepatitis (sAH) is a well-characterized disease with high short-term mortality. However, there is limited research on those with a “less severe condition” (moderate AH). This study aims to characterize in-depth patients with moderate AH (mAH), including the performance of mortality scoring systems, key prognostic factors, and survival over time. Methods: A multicenter retrospective cohort study (2009–2019) included patients with mAH (MELD score ≤20 at admission). Cox regression and receiver operating characteristic curves with AUC were used for analysis. Results: We included 1845 patients with AH (20 centers, 8 countries) between 2009 and 2019. mAH was defined as a MELD score ≤20 at admission. Twenty-four percent met the criteria for an mAH episode. Patients with mAH tend to be older and have a higher proportion of females, with a median MELD of 17 (15–19), Maddrey discriminant function (mDF) of 33 (22–40), the trajectory of serum bilirubin of 0.83 (0.60–1.21), and neutrophil-to-lymphocyte ratio (NLR) of 5 (2.96–8.60). The primary causes of death in mAH included multiple organ failure (34.1%) and infections (16.6%). The cumulative survival rates at 30, 90, and 180 days were 94.3%, 90.4%, and 88.2%, respectively. In multivariable analysis, age was the only significant predictor of 30-day mortality (HR 1.49, 95% CI: 1.27–1.76, p <0.001). Mortality prediction models showed poor performance, with AUC for MELD (0.671), mDF (0.726), trajectory of serum bilirubin (0.733), and NLR (0.697). Conclusions: Patients with moderate AH exhibited a mortality of 11.8% at 6 months, primarily driven by multiple organ failure and infections. These patients also exhibit a different clinical profile compared to those with sAH. Tailored models and therapeutic strategies are needed to improve long-term outcomes in mAH.
Associations between neuropsychiatric symptoms and pathology in clinicopathologically defined Alzheimer's disease, Alzheimer's disease with Lewy bodies, and dementia with Lewy bodies
Tremblay, Cécilia , Shakir, Neha , Zhang, Nan , Adler, Charles H. , Shill, Holly A. , Mehta, Shyamal H. , Driver‐Dunckley, Erika , Belden, Christine M. , Beach, Thomas G., Mehta, Shyamal , Serrano, Geidy E , Choudhury, Parichita , Belden, Christine , Adler, C H , Atri, Alireza , Beach, Thomas G. , Serrano, Geidy E. , Choudhury, Parichita

Mayo Clinic

Journal of Alzheimer’s Disease | March 14, 2025 | Volume: 104 | Issue: 3 | Pages: 933-942

10.1177/13872877251320670 | PMID 40084663 Get It

Background Neuropsychiatric symptoms (NPS) are frequent in Alzheimer's disease (AD) dementia, but a higher NPS burden is found in dementia with Lewy bodies (DLB). Lewy body (LB) pathology frequently co-occurs with AD pathology and may not meet neuropathological criteria for DLB (ADLB). NPS trajectories over disease course in these subgroups is not well understood. Objective We investigated changes in NPS severity over time, at two time points, comparing clinicopathologically defined cohorts of AD (without LB), ADLB, DLB, and controls. Methods Cases with two available Neuropsychiatric Inventory-Questionnaire (NPIQ), at the time of enrollment and within 2.5 years of death, were selected from the Arizona Study of Aging and Neurodegenerative Disorders. Differences and rate of change in NPIQ scores were compared between AD (n = 75), ADLB (n = 48) DLB (n = 65), and controls (n = 32) with covariates for age, sex, and cognition. Results First NPIQ scores were highest in ADLB when compared to AD (p = 0.04) and controls (p = 0.01) but not different from DLB. A significant increase in NPS severity was observed in DLB and AD (p < 0.001) over a mean follow up time of 4.9 ± 3.0 years, and the rate of change was significantly greater in DLB when compared to other groups. Final NPIQ scores were highest in DLB when compared to AD (p = 0.03) but not ADLB, and in DLB, ADLB, and AD than controls ( all p < 0.001). Conclusions Early NPS burden as well as NPS severity progression rate, independently of cognitive status, might be useful clinical metrics and may help predict underlying pathological diagnoses.
Escalation of Oxygenation Modalities and Mortality in Critically Ill Immunocompromised Patient With Acute Hypoxemic Respiratory Failure: A Clustering Analysis of a Prospectively Multicenter, Multinational Dataset
Yvin, Élise, Kouatchet, Achille, Mokart, Djamel, Martín‐Loeches, Ignacio , Seguin, Amélie, Louw, Andry van de, Mabrouki, Asma, Bredin, Swann, Klouche, Kada , Mehta, Sangeeta , Bruneel, Fabrice , Lisboa, Tiago, Viana, William, Pickkers, Peter , Russell, Lene , Rusínová, Kateřina , Rello, Jordi, Clère-Jehl, Raphaël , Lafarge, Antoine , Lemiale, Virginie , Mercat, Alain , Russell, Lene , Martin-Loeches, Ignacio , Kouatchet, Achille, Mokart, Djamel , Taccone, Fabio Silvio , Pène, Frédéric , Bauer, Philippe R. , Seguin, Amélie, Metaxa, Victoria , Montini, Luca , Lisboa, Tiago, Rello, Jordi , Barbier, Francois, Azoulay, Élie , Darmon, Michaël

Mayo Clinic

Critical Care Medicine | February 27, 2025 | Volume: 53 | Issue: 5 | Pages: e1055-e1065

10.1097/ccm.0000000000006600 | PMID 40013850 Get It

OBJECTIVES: Acute hypoxemic respiratory failure in immunocompromised patients remains the leading cause of admission to the ICU, with high case fatality. The response to the initial oxygenation strategy may be predictive of outcome. This study aims to assess the response to the evolutionary profiles of oxygenation strategy and the association with survival. DESIGN: Post hoc analysis of EFRAIM study with a nonparametric longitudinal clustering technique (longitudinal K-mean). SETTING AND PATIENTS: Multinational, observational prospective cohort study performed in critically ill immunocompromised patients admitted for an acute respiratory failure. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: A total of 1547 patients who did not require invasive mechanical ventilation (iMV) at ICU admission were included. Change in ventilatory support was assessed and three clusters of change in oxygenation modality over time were identified. Cluster A: 12.3% iMV requirement and high survival rate, n = 717 patients (46.3%); cluster B: 32.9% need for iMV, 97% ICU mortality, n = 499 patients (32.3%); and cluster C: 37.5% need for iMV, 0.3% ICU mortality, n = 331 patients (21.4%). These clusters demonstrated a high discrimination. After adjustment for confounders, clusters B and C were independently associated with need for iMV (odds ratio [OR], 9.87; 95% CI, 7.26–13.50 and OR, 19.8; 95% CI, 13.7–29.1). CONCLUSIONS: This study identified three distinct highly performing clusters of response to initial oxygenation strategy, which reliably predicted the need for iMV requirement and hospital mortality.